These oral agents showed overall response rates (ORRs) of 37% and 23.1%, respectively, in phase II single-arm clinical trials that enrolled patients with advanced CCA harboring FGFR2 fusions or rearrangements (Table 2) [125, 126], leading to Food and Drug Administration (FDA) Accelerated Approval in April 2020 and May 2021. This evidence concerns the gene FGFR2 and cholangiocarcinoma.